arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Merck & Company, Inc.

MRK Health Care Biotechnology: Pharmaceutical Preparations
$147.24
▼ -0.7% Today
as of Oct 22, 16:50 ET
Last 30 days +1.65% Sep 14 → Oct 22
$138.63 $141.93 $145.22 $148.52 $151.82 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$151.05
High
$154.02
Low
$144.07
Volume
$19M
Avg Vol
$11M
Mkt Cap
$352.3B
P/E (TTM)
—
Beta
—
52w High
$156.92
52w Low
$82.01
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 25 items

mixed ▲ 1 ● 24 ▼ 0
Oct 21 · 20:45 Zacks neutral
Merck (MRK) Laps the Stock Market: Here's Why
Oct 21 · 11:16 MT Newswires neutral
Merck Wins EU Approval for Keytruda-Padcev Combination in Bladder Cancer
Oct 21 · 02:20 Trefis neutral
What Happens To Merck Stock If Keytruda Sales Stop Growing?
▸ Show all 25 press releases & news Free account →

MRK earnings at a glance

Merck & Company, Inc. (MRK) is scheduled to report earnings on Thursday, October 29, 2026 before the market opens — in 6 days. Analysts expect earnings per share of $2.14, compared with $2.58 in the same quarter last year (-17%). The options market is pricing a move of about ±7.5% after the report, a range of roughly $136.17 to $158.31 from today's $147.24. Over its last 6 reports the stock rose the next day 3 times and fell 3, moving ±1.2% on average; after the most recent report on Aug 4, 2026 it moved +0.2%. That means options currently expect more movement than MRK has typically delivered. MRK beat the consensus EPS estimate in 6 of its last 6 reported quarters. Implied volatility is currently 38%. The share price of $147.24 sits near its 52-week high.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$82
$157
87% of range
Avg surprise (last 6)
+14.0%
Avg reaction (last 6)
+0.0%
50% positive
Latest IV / EM
38%
EM ±7.5% · $142 · Oct 30

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.35$-1.12$0.11$1.35$2.58 Actual $1.11Actual $-2.35Actual $1.86Actual $1.87Actual $2.14Actual $1.24Actual $2.22Est $2.15Actual $2.13Est $2.01Actual $2.58Est $2.36Actual $2.04Est $2.03Actual $-1.28Est $-1.51Actual $-0.13Est $-0.26 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258K8KJun/2026
Revenue vs Net Income Revenue Net income
$-4.2B$1.4B$6.9B$12.5B$18.1B Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Aug 4, 2026Jun/2026 $-0.13 $-0.26 +50.0% -112.2% +0.2% earnings
Thu Apr 30, 20268K 2026-04-30 $-1.28 $-1.51 +15.2% — -1.6% earnings
Tue Feb 3, 20268K 2026-02-03 $2.04 $2.03 +0.5% — +2.2% earnings
Thu Oct 30, 2025Sep/2025 $2.58 $2.36 +9.3% — -0.3% earnings
Tue Jul 29, 2025Jun/2025 $2.13 $2.01 +6.0% — -1.7% earnings
Thu Apr 24, 2025Mar/2025 $2.22 $2.15 +3.3% — +1.4% earnings
Mon Sep 30, 2024Sep 2024 $1.24 — — — — financials
Sun Jun 30, 2024Jun 2024 $2.14 — — — — financials
Sun Mar 31, 2024Mar 2024 $1.87 — — — — financials
Sat Sep 30, 2023Sep 2023 $1.86 — — — — financials
Fri Jun 30, 2023Jun 2023 $-2.35 — — — — financials
Fri Mar 31, 2023Mar 2023 $1.11 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Oct 29, 2026Sep/2026BMO $2.14$2.58 -17.1%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$16.61B$16.29B—$17.28B$15.81B$15.53B—$16.66B
Cost of revenue$4.39B$4.20B—$3.85B$3.56B$3.42B—$4.08B
Gross profit————————
Operating income————————
Net income$-1.33B$-4.24B—$5.79B$4.43B$5.08B—$3.16B
EPS (diluted)$-0.54$-1.72—$2.32$1.76$2.01—$1.24

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$6.85B$5.33B$14.56B$18.17B$8.01B$8.63B$13.24B$14.59B
Inventory$6.21B$6.48B$6.66B$6.44B$6.60B$6.20B$6.11B$6.24B
Total current assets$36.68B$35.02B$43.52B$47.56B$37.06B$35.50B$38.78B$40.36B
Total assets$129.80B$128.69B$136.87B$129.55B$117.52B$115.12B$117.11B$117.53B
Long-term debt$51.08B$46.67B$46.75B$39.97B$33.97B$33.48B$34.46B$34.98B
Total liabilities————————
Total equity$41.93B$45.93B$52.61B$51.85B$49.06B$48.40B$46.31B$44.56B

Implied volatility — last 90 days

25%204%383%562%741% Jun 07 — IV 34% · EM ±3.2%Jun 08 — IV 34% · EM ±2.9%Jun 09 — IV 36% · EM ±2.6%Jun 10 — IV 36% · EM ±2.1%Jun 11 — IV 32% · EM ±1.3%Jun 15 — IV 37% · EM ±2.7%Jun 16 — IV 37% · EM ±2.2%Jun 17 — IV 36% · EM ±1.5%Jun 19 — IV 30% · EM ±3.3%Jun 22 — IV 33% · EM ±2.8%Jun 23 — IV 35% · EM ±2.6%Jun 24 — IV 32% · EM ±1.9%Jun 25 — IV 33% · EM ±1.4%Jun 29 — IV 26% · EM ±6.0%Jun 30 — IV 26% · EM ±6.1%Jul 01 — IV 39% · EM ±1.6%Jul 03 — IV 28% · EM ±3.1%Jul 06 — IV 32% · EM ±2.7%Jul 07 — IV 33% · EM ±2.4%Jul 08 — IV 33% · EM ±2.0%Jul 09 — IV 35% · EM ±1.5%Jul 13 — IV 31% · EM ±2.6%Jul 14 — IV 37% · EM ±2.7%Jul 15 — IV 35% · EM ±2.0%Jul 16 — IV 33% · EM ±1.4%Jul 20 — IV 31% · EM ±2.6%Jul 21 — IV 30% · EM ±2.2%Jul 22 — IV 32% · EM ±1.9%Jul 23 — IV 31% · EM ±1.3%Jul 27 — IV 32% · EM ±2.7%Jul 28 — IV 31% · EM ±2.3%Jul 29 — IV 38% · EM ±2.2%Jul 30 — IV 36% · EM ±1.5%Aug 03 — IV 58% · EM ±4.8%Aug 04 — IV 40% · EM ±2.9%Aug 05 — IV 40% · EM ±2.4%Aug 06 — IV 37% · EM ±1.6%Aug 10 — IV 29% · EM ±2.5%Aug 11 — IV 29% · EM ±2.1%Aug 12 — IV 26% · EM ±1.6%Aug 13 — IV 35% · EM ±1.5%Aug 17 — IV 29% · EM ±2.4%Aug 18 — IV 29% · EM ±2.1%Aug 19 — IV 57% · EM ±3.4%Aug 20 — IV 37% · EM ±1.5%Aug 24 — IV 37% · EM ±3.1%Aug 25 — IV 36% · EM ±2.6%Aug 26 — IV 30% · EM ±1.8%Aug 27 — IV 741% · EM ±31.0%Aug 31 — IV 30% · EM ±2.5%Sep 01 — IV 32% · EM ±2.3%Sep 02 — IV 28% · EM ±1.7%Sep 03 — IV 32% · EM ±1.3%Sep 07 — IV 32% · EM ±2.7%Sep 08 — IV 33% · EM ±2.4%Sep 09 — IV 36% · EM ±2.1%Sep 10 — IV 32% · EM ±1.3%Sep 14 — IV 33% · EM ±2.7%Sep 15 — IV 32% · EM ±2.3%Sep 16 — IV 34% · EM ±2.0%Sep 17 — IV 31% · EM ±1.3%Sep 21 — IV 29% · EM ±2.5%Sep 22 — IV 34% · EM ±2.5%Sep 23 — IV 32% · EM ±1.9%Sep 24 — IV 31% · EM ±1.3%Sep 28 — IV 36% · EM ±8.4%Sep 29 — IV 36% · EM ±8.4%Sep 30 — IV 38% · EM ±8.7%Oct 01 — IV 36% · EM ±8.2%Oct 02 — IV 35% · EM ±7.7%Oct 06 — IV 37% · EM ±7.6%Oct 07 — IV 38% · EM ±7.5%Oct 08 — IV 38% · EM ±7.5%

Sector peers

NVS
Novartis AG
$273.4B $156.27+1.7%
ABBV
AbbVie Inc.
$479.5B $285.19-1.4%
ABT
Abbott Laboratories
$170.8B $102.51+0.1%
NVO
Novo Nordisk A/S
$169.4B $39.43+0.2%
VRTX
Vertex Pharmaceuticals Incorporated
$128.2B $535.17+4.0%
SNY
Sanofi
$98.0B $41.96+1.4%

MRK earnings FAQ

When is MRK's next earnings date?

Merck & Company, Inc. is expected to report on October 29, 2026, before the market opens.

What is MRK's expected move for earnings?

Options currently price a move of about ±7.5%, or $11.07 per share either way from $147.24.

How does MRK stock usually react to earnings?

Across the last 6 reports the average next-day move was ±1.2%, up 3 times and down 3 times.

What EPS are analysts expecting from Merck & Company, Inc.?

The consensus estimate is $2.14 per share, versus $2.58 a year ago.

What is MRK's implied volatility?

MRK's at-the-money implied volatility is about 38% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in